Bora Pharmaceuticals Subsidiary Signs 10-Year Long-Term Manufacturing Agreement with Top 20 Global Pharma Company
Bora Corporation's subsidiary, Bora Pharmaceuticals Inc., has signed a 10-year long-term contract manufacturing agreement with a top 20 global pharmaceutical company. The agreement covers a range of services including development, manufacturing, packaging, and analysis. This strategic move strengthens Bora's position as a long-term CDMO partner for international pharmaceutical firms and is expected to positively impact future revenue and operational scale, furthering its expansion into new drug and biologics manufacturing.
📋 Article Processing Timeline
- 📰 Published: May 19, 2026 at 06:31
- 🔍 Collected: May 19, 2026 at 06:31 (0 min after Published)
- 🤖 AI Analyzed: May 19, 2026 at 07:04 (33 min after Collected)
Date of form submission: 115/05/19 Date of announcement: 115/05/18 Time of announcement: 18:21:47 Company Code: 6472 Company Name: Bora Subject: Announcement on behalf of subsidiary Bora Pharmaceuticals Inc. regarding the signing of a long-term contract manufacturing agreement. Applicable clause: Article 10. Date of occurrence: 115/05/18. Description: 1. Date of occurrence: 115/05/18 2. Counterparty to the contract or commitment: Trading partner (undisclosed per confidentiality agreement) 3. Relationship with the company: Non-related party 4. Start and end date of the contract or commitment (or termination date): Effective from the date of signing for a period of 10 years, with an automatic renewal for 2 years upon expiration. 5. Main content (not applicable for termination): To provide various support services including but not limited to development, manufacturing, packaging, and analysis during the contract period. 6. Restrictive clauses (not applicable for termination): As per contract provisions. 7. Commitments (not applicable for termination): To comply with and cooperate with ESG regulations; other items as per contract provisions. 8. Other important agreements (not applicable for termination): As per contract provisions. 9. Impact on the company's finance and business: Positive benefits for the company's future revenue and operational scale. 10. Specific purpose: To strengthen Bora's position as a long-term CDMO strategic partner for international pharmaceutical companies, to continue expanding the CDMO business, and to actively enter the field of new drug and biologics manufacturing. 11. Other matters to be specified: The counterparty is a top 20 global pharmaceutical company.